quimopapaína

Chymopapain

Identity and Chemical Characterization

Chymopapain (EC 3.4.22.6; synonyms: chymopapain A, chymopapain B, chymopapain S; former brand names: Chymodiactin, Discase) is a proteolytic enzyme isolated from the latex of papaya (Carica papaya). It is a cysteine protease belonging to the papain-like protease (PLCP) group. It is characterized as a sulfhydryl enzyme similar to papain, but differs with respect to substrate specificities, electrophoretic mobility, stability, and solubility. Chymopapain is known for its stability at acid pH and high solubility in salt solutions, with activities characterized by a higher ratio of milk-clotting to hemoglobin-digesting compared to trypsin and papain.

Chymopapain's zymogen is made up of a total of 352 residues and has a weight of approximately 23.78 kDa. Chymopapain presents three disulfide bonds as post-translational modifications established between residues 156–197, 190–229, and 287–338. It exists in at least two forms, chymopapain A and B, which can be separated by cation-exchange chromatography.

Chymopapain (EC 3.4.22.6) can be purified from commercially available spray-dried latex of papaya (Carica papaya) fruit by ammonium sulfate fractionation and fast protein chromatography on a Mono S cation-exchange column. Latex from fresh unripe papaya fruit contains predominantly one form of chymopapain, and it has been concluded that chymopapain is a single enzyme distinct from the other cysteine proteinases of C. papaya latex.

Papaya latex proteases are composed of cysteine proteases which contribute 69–89% of total protein, with less than 10% papain, 26–30% chymopapain, 23–28% glycyl endopeptidase, and 14–26% caricain. These four proteases have similar molecular weights of approximately 23 kDa.

Botanical Source

The seeds, skin, leaves, latex, and fruit of the papaya contain several enzymes; among them, the most important are papain and chymopapain. The proteases present in the latex of the fruit are inactive precursors that are activated once the papaya is wounded; in 0.3 ml of latex there are approximately 15 mg of chymopapain. Papain (and with it chymopapain) is primarily produced by creating cuts in the unripe papaya fruit's epicarp, gathering, and drying the latex that leaks out; greener fruit produces more active enzyme.

Preparation and Stability

To conserve proteolytic properties, latex has to be preserved with sodium metabisulfite and stored at approximately −10°C. If used immediately after incision, a buffer is added to extract the proteins — EDTA, ammonium sulfate, or phosphate buffer, each at a concentration of 0.5 mM and a pH of 7. It is also important to block thiol functions to avoid air oxidation and loss of proteolytic activity.

In 1979, Smith Laboratories introduced a purer chymopapain formulation under the name Chymodiactin. Chymodiactin consisted of chymopapain along with sodium cysteinate hydrochloride, a stabilizer with properties of a reducing agent. Chymodiactin did not contain sodium bisulfite or edetic acid, which were removed from previous formulations to decrease the likelihood of adverse events and to increase drug stability. Purified chymopapain was the main component of the injection, approximately 20 mg in five millilitres. It was provided in vials containing 10,000 units of the lyophilized agent with 0.37 mg of disodium edetate, 3.5 mg of cysteine hydrochloride monohydrate, and 1.0 mg of bisulfide, all functioning as stabilizers and activators.

Historical and Traditional Use

Ethnobotanical Context of Carica papaya

Chymopapain as an isolated compound has no independent history in traditional medicine; however, it is one of the principal active constituents responsible for the documented medicinal properties of papaya latex and fruit, which have a long history of use across multiple cultures. In traditional medical cultures, papaya (peel, pulp, seeds, rarely leaves and latex) has been primarily used to treat asthma, parasitoses, wound healing disorders, as well as gastrointestinal problems such as diarrhea or constipation. The ingredients were understood to stimulate and regulate digestive activity, mitigate gastric hyperacidity, reduce excessive gas formation, and support the breakdown of proteins. Possible healing effects were first reported in writing by the Spaniard Oviedo in 1526.

Papaya has been widely used in folk medicine for many ailments: the juice for warts, corns, cancers, tumors, and indurations of the skin; the roots or their extracts for uterine tumors, syphilis, yaws, or hemorrhoids, and to remove urine concretions; the unripe fruit for mild laxative or diuretic properties, and to stimulate lactation, labor, or abortion; the ripe fruit for rheumatism and alkalinizing the urine; the seeds for their anthelmintic properties or to stimulate menstruation or abortion; the leaves as a poultice for nervous pains and elephantoid growths, or smoked for asthma relief; and the latex for psoriasis, ringworm, or dyspepsia, or applied externally as an antiseptic or to heal burns or scalds, or smeared on the cervix as an ecbolic.

Different parts of the plant — including leaves, fruits, seeds, latex, and roots — have been used in Ayurveda, folk medicine, and ethnomedicine for treating digestive disorders, infections, inflammation, diabetes, dengue fever, and parasitic infestations. Fruits and fresh leaves are routinely used to facilitate digestion; in traditional medicines, fresh leaves are also sometimes used as local anti-inflammatories.

First Scientific Isolation

Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It was first characterized and described by Jansen and Balls, J. Biol. Chem., vol. 137, pp. 459–60 (1941) and in U.S. Patent No. 2,313,875 (1943).

Early Medical Application: Chemonucleolysis

In 1959, Hirsh suggested the use of proteolytic enzymes for the treatment of discal hernia sciatica. Smith, influenced by the studies of Thomas on papain action on cartilage proteoglycans, undertook a series of experimental studies in 1963 to demonstrate that intradiscal injection of a proteolytic enzyme was a possible non-surgical treatment for discal hernia. In 1964 he published the first clinical results of intradiscal chymopapain injection, an enzyme chosen for its high specificity and low toxicity. The oldest intradiscal therapy is chemonucleolysis with chymopapain.

Key Constituents and Active Compounds

Chymopapain is itself the active compound of interest. Its cysteine protease activity is central to all documented mechanisms. Proteases in Carica papaya are cysteine proteases which need small reducing agents such as cysteine to activate them before catalysis. These reducing agents convert reversibly inactive forms of enzymes to the active forms and protect their essential thiol group from oxidation.

Scientific investigations have identified numerous bioactive phytoconstituents in papaya such as papain, chymopapain, flavonoids, alkaloids, phenolics, and carotenoids that contribute to its pharmacological properties. Chymopapain shares many of its properties with two other cysteine endopeptidases from the same source, papain and caricain. Differences in substrate specificity and inhibition profiles between these enzymes have been detected, but are not remarkable.

The main structural difference between chymopapain and other papaya proteinase proteins such as papain or caricain is in two distinct turns, with these enzymes otherwise having similar conformations.

Established Mechanisms of Action

Primary Mechanism: Proteoglycan Hydrolysis in the Intervertebral Disc

Chymopapain catalyzes the hydrolytic cleavage of glycosaminoglycans from proteoglycan aggregates in the disc. This results in nucleus pulposus contraction secondary to decreased hydration. More specifically, chymopapain works by depolymerizing the proteoglycan and glycoprotein molecules in the nucleus pulposus. These large molecules are responsible for water retention and turgidity. When exposed to chymopapain, the water content within the disc decreases, resulting in shrinkage and thereby causing a reduction in disc height and girth.

Chymopapain is a catalyst for the cleavage of glycosaminoglycans from proteoglycan aggregates in the disc. These reactions decrease the water-binding capacity of the polysaccharide side chains, and as a result of decreased disc pressure, disc protrusion decreases and there is less tension on nerve roots.

Chymopapain is responsible for catalyzing, both in vivo and in vitro, a rapid reduction in the viscosity and, as a consequence, the weight of the nucleus pulposus. This constitutes a depolymerization of chondromucoprotein and a decrease in the ability of a disc to imbibe fluid.

Disc Biochemistry After Injection: Animal Data

Animal model studies have provided detailed insight into the biochemical sequence following chymopapain injection. The proteoglycan was degraded to glycosaminoglycans within 1 week after chymopapain treatment. Two weeks later, a proteoglycan smaller than the original appeared in the nucleus pulposus. At 8 weeks after injection, the amount of newly synthesized proteoglycan, similar in molecular weight to the original, had recovered to about half that of the original, although the new proteoglycan fraction was rich in hyaluronic acid. It was concluded that, following chemonucleolysis with chymopapain, the water-binding capacity of the nucleus pulposus recovered, but the regenerated nucleus pulposus differed biochemically from the original.

Histological studies in dogs further elucidated the process: in the adult mongrel dog, in vivo injection of chymopapain into the intervertebral disc resulted in disc-space narrowing at two weeks, with a complete loss of proteoglycan from the nucleus pulposus, cartilaginous end-plates, and the annulus fibrosus. The nucleus pulposus retained the ability to synthesize proteoglycans, but these were degraded by endogenous proteolytic activity. Three months after chymopapain treatment the intervertebral disc showed an increase in height, with a return of intense proteoglycan staining in the annulus, cartilaginous end-plates, and nucleus. The proteoglycans were recovered as aggregates. At six months following chymopapain treatment, proteoglycans of similar characteristics to normal canine intervertebral disc were identified, with a glucosamine/galactosamine ratio approaching normal values.

Observations from these studies demonstrated that chymopapain has a profound but reversible effect on the intervertebral disc. The radiographic narrowing of the intervertebral disc following chymopapain injection correlates with the loss of proteoglycan content and structure. The restoration of normal disc height following chymopapain injection is explained by reconstitution of the intervertebral disc with normal proteoglycans. In experimental animals, chemonucleolysis with chymopapain appears to be less likely than surgical excision to permanently alter the biochemistry of the nucleus pulposus.

Fibrinolytic and Anti-Inflammatory Activity

Papain and chymopapain have fibrinolytic activity, which means that the edema formed during certain inflammatory reactions can be reduced. The papaya fruit (Carica papaya) contains several proteolytic enzymes (papain, chymopapain A, chymopapain B, and papaya peptidase A) and is mainly used in wound débridement. However, clinical evidence for anti-inflammatory or fibrinolytic effects specifically attributable to isolated chymopapain — as distinct from broader papaya-derived proteolytic preparations — is limited in the scientific literature.

Scientific Evidence by Area of Use

1. Chemonucleolysis for Lumbar Disc Herniation

This is by far the most thoroughly studied clinical application of chymopapain. The available evidence base encompasses randomized controlled trials (RCTs), long-term cohort studies, and multiple systematic reviews and meta-analyses.

Landmark RCTs

In a randomized controlled trial in patients with lumbar disc herniation (N=108), Javid et al. demonstrated that Chymodiactin was more efficacious than placebo, with a success rate of 82% versus 41% placebo at 6 months after treatment administration.

A double-blind, randomized trial was conducted to compare the efficacy of intradiscal injection of chymopapain (Chymodiactin) with injection of placebo in patients with a herniated lumbar disc. Patients were randomly assigned to either placebo or drug regimens and followed for six months. The primary measure of performance was agreement by patient and surgeon that further intervention was not necessary. Of 53 placebo-treated patients, 31 failed by this criterion; of 55 drug-treated patients, 15 failed. Placebo-treated patients who failed were allowed to receive drug treatment, and 29 (91%) of 32 were treated successfully. This study demonstrated that chymopapain is more effective than placebo for treatment of patients with a herniated lumbar disc.

A notable dissenting early RCT also exists: in 66 patients with signs, symptoms, and myelographic abnormality of herniated lumbar disc who were not responsive to conservative treatment, discs were injected at random with either chymopapain or placebo. Neither patient nor surgeon knew which agent was used until after results had been tabulated. Unless early laminectomy was necessary, all patients were followed for 2 months or more. There was no statistically significant difference in incidence or quality of improvement between the two groups: chymopapain was successful in 58% while placebo was successful in 49% (p = 0.15). The early results from this study indicated that most of the putative effectiveness of chemonucleolysis probably derived from a placebo effect. This study is notable but has been considered an outlier in the context of the larger body of evidence.

Prospective Randomized Comparative Studies

A 5-year clinical follow-up assessment of a prospective randomized study of chemonucleolysis using chymopapain (4000 IU) or collagenase (400 ABC units) was performed. In this study, 100 patients with indication for intradiscal therapy were prospectively randomized to treatment with either chymopapain or collagenase. All injections were performed by the double-needle technique with patients under general anesthesia. The mean age of patients was 35.5 years in the chymopapain group and 38 years in the collagenase group. After 5 years, no deterioration had occurred as compared with the 1-year follow-up assessment. Chymopapain proved to be safe, with one minor anaphylactic reaction, and effective even over the long term. Collagenase was considered to need further study at that time.

Another comparative study in 100 patients prospectively randomized to chymopapain (n=50, 4000 IU) or collagenase found: the success rate after 1 year was 70% for collagenase and 78% for chymopapain, and 72%/80% after 3 years, respectively.

Long-Term Follow-Up Data

A follow-up evaluation of 357 patients injected with chymopapain ten to twenty years earlier included 97 females of mean age 42.2 years and 260 males of mean age 41.6 years. Post-injection, significant back pain persisted less than 24 hours in seven patients, less than six days in 133, and less than 21 days in 178. Leg pain remained less than 24 hours in 32 patients, between one and five days in 212, and between six and 21 days in 96.

In a retrospective correlation of pretreatment radiographs and clinical responses in 200 consecutive chemonucleolysis patients, marked improvement in sciatica occurred in 79.9% and 79.3% of patients at early and late follow-up, respectively. There was a significantly higher response rate in patients who had definite radiographic evidence of focal disc herniation and in those patients with definite radiographic evidence of nerve-root compression.

Systematic Reviews and Meta-Analyses

A meta-analysis of 22 eligible clinical trials drawn from the Cochrane Controlled Trials Register, MEDLINE, and EMBASE found that for chemonucleolysis versus placebo, the summary risk ratio estimate for pain relief was 1.51 (95% CI: 1.27–1.80). The summary estimate was 1.07 (95% CI: 0.95–1.20) for the comparison between chymopapain and collagenase. This review concluded that chemonucleolysis with chymopapain was superior to placebo and as effective as collagenase, but heterogeneity between studies in the comparison with surgery made interpretation difficult. Given the small number of studies included, the potential for missed studies and apparent publication bias, the conclusions should be interpreted with some caution.

Three randomized clinical trials demonstrated that chymopapain was superior to placebo in patients with lumbar disc herniation-associated radicular leg pain that did not respond to conservative therapy. In a meta-analysis of 5 high-quality, randomized clinical trials (N=446 patients), chemonucleolysis with chymopapain was found to be more effective than placebo whether rated by the patient, surgeon, or an independent observer.

The most comprehensive recent systematic review, published in Scientific Reports (2024), found: among 62 included studies (12,368 patients), chemonucleolysis demonstrated a 79% treatment success rate and significantly outperformed placebo controls (OR 3.35, 95% CI 2.41–4.65), and scored similarly to surgical interventions (OR 0.65, 95% CI 0.20–2.10). Serious adverse events occurred in 1.4% of cases, with slightly higher rates in chymopapain cohorts.

A 2025 meta-analysis comparing chemonucleolysis versus discectomy found: discectomy had a significantly higher improvement rate compared with chymopapain chemonucleolysis (OR: 0.45; 95% CI 0.23–0.88). A non-significant inclination towards complication rates was observed with chymopapain chemonucleolysis (OR: 1.90; 95% CI 0.68–5.29). Notably, chemonucleolysis was associated with considerable cost reduction and shorter surgical time compared with discectomy. The evidence suggests superior clinical outcomes for discectomy when compared to chemonucleolysis in managing lumbar disc herniation; however, chemonucleolysis demonstrated a notable advantage in cost-efficiency and operative time.

Comparisons to Surgery: Historically Contested

Following the 1982 FDA approval of chymopapain for public use in the treatment of ruptured lumbar intervertebral disc disease, chemonucleolysis became widespread in the United States. Some analyses concluded that chemonucleolysis is not as efficacious as surgery for simple ruptured lumbar intervertebral disc disease, and that while the complication rates are probably no greater than those for surgery, the incidence of unpreventable anaphylaxis and other reactions makes it no more safe. This view was disputed by other researchers, and the balance of evidence from meta-analyses is that chymopapain achieves results similar to or somewhat inferior to surgery, with meaningful cost and time advantages.

Selectivity of Benefit: Patient Selection Factors

Patients fulfilling three or four of the following four immediate pre-treatment clinical and radiographic criteria — sciatica more severe than back pain, reduced straight leg raising, neurological deficit, radiographic abnormality — had a satisfactory response more often than others (p < 0.05). The procedure predominantly relieves radicular pain rather than back pain. Chymopapain has been shown to be safe and effective in patients aged 60 to 80, provided there is adequate hydration of the disc.

2. Digestive Enzyme / Protein Digestion (Oral Use)

Chymopapain is used as a digestant of protein. The papaya fruit contains several proteolytic enzymes (papain, chymopapain A, chymopapain B, and papaya peptidase A) and papaya-derived preparations are mainly used in wound débridement. However, clinical evidence specifically isolating chymopapain's digestive contribution from the broader enzyme profile of papaya preparations is absent in the peer-reviewed literature; published over-the-counter enzyme supplement reviews discuss papaya proteases collectively rather than chymopapain individually. Some enzymes from papaya are sold directly to consumers, including papain, trypsin, and chymotrypsin, as well as numerous combination products. There are no rigorously designed RCTs establishing a specific clinical indication for oral isolated chymopapain as a digestive supplement.

3. Wound Débridement (Topical)

The papaya fruit contains several proteolytic enzymes and is mainly used in wound débridement, with chymopapain as one component. Papaya fruits are used as topical ulcer dressings in Jamaica. Available clinical evidence in this context applies to broad papain-containing preparations rather than specifically isolated chymopapain, and the evidence base is weak and largely restricted to case series and small studies.

4. Potential Anti-Inflammatory Activity

Papain and chymopapain have fibrinolytic activity, which means that the edema formed during certain inflammatory reactions can be reduced. In addition to anti-inflammatory effects, proteases are administered orally for digestive enzyme replacement and for potentiation of drug effects, especially of antibiotics. Some of the more commonly used proteases in research studies and clinical practice include pancreatin, trypsin, chymotrypsin, bromelain, papain, and chymopapain. No human RCTs specifically testing isolated chymopapain for systemic anti-inflammatory outcomes have been identified in the peer-reviewed literature; evidence for this application remains largely preclinical or extrapolated from studies on mixed proteolytic enzyme formulations.

Body Systems and Health Areas of Association

• Musculoskeletal / Spinal: The primary documented clinical application; chymopapain injection has been used for lumbar intervertebral disc herniation with sciatica. Because of its proteolytic activity, it is the main molecule in the process of chemonucleolysis, used in the treatment of herniated lower lumbar discs in the spine by a non-surgical method.
• Digestive: As a constituent of papaya latex, chymopapain contributes to protein digestion. Carica papaya contains proteolytic enzymes like papain and chymopapain which have antiviral, antifungal, and antibacterial properties and can be used for treatment of numerous diseases including dyspepsia and constipation.
• Inflammatory response: In traditional medicines, fresh papaya leaves are also sometimes used as local anti-inflammatories; papain and chymopapain have fibrinolytic activity, which means that edema formed during certain inflammatory reactions can be reduced.
• Wound healing / dermatological: The papaya latex has traditional use for psoriasis, ringworm, or dyspepsia, or applied externally as an antiseptic or to heal burns or scalds.

Regulatory and Commercial History

In 1982, the FDA approved for commercial release Smith Laboratories' Chymodiactin and Travenol's Discase brands of chymopapain. Around 1999, Abbott Pharmaceuticals discontinued production of Chymodiactin, effectively withdrawing chymopapain from the market for reasons which were not entirely clear. The FDA announced its determination that Chymodiactin (chymopapain 10,000 units/vial injection) was not withdrawn from sale for reasons of safety or effectiveness; this determination would allow the FDA to approve abbreviated new drug applications (ANDAs) for chymopapain 10,000 units/vial injection.

The chymopapain studies were predominantly conducted in North America and Europe before 2000, whereas condoliase and collagenase studies were primarily performed in Asia, with condoliase being carried out mostly after 2015. Contemporary research has borne witness to a potential renaissance in chemonucleolysis, with condoliase, a chondroitin sulfate ABC endolyase (also known as chondroitinase ABC), emerging as a novel and potentially more targeted alternative. It has been verified that condoliase is significantly less harmful to the surrounding tissues, and the nervous and vascular system than chymopapain.

Dosage Forms and Reported Dosages

Chymopapain was developed and used exclusively as a parenteral intradiscal injection in its approved pharmaceutical form. It was not developed or approved as an oral supplement in isolated form.

• Purified chymopapain was provided as approximately 20 mg in five millilitres in vials containing 10,000 units of the lyophilized agent with 0.37 mg of disodium edetate, 3.5 mg of cysteine hydrochloride monohydrate, and 1.0 mg of bisulfide.
• In a prospective randomized study, 50 patients received chymopapain at a dose of 4000 IU.
• A 5-year prospective randomized study used chymopapain at 4000 IU per disc.
• In chymopapain studies, injected volumes and concentrations ranged between 1.0–2.5 mL and 1000–2000 UI/mL, respectively.
• Chymodiactin (chymopapain 10,000 units/vial injection) was indicated for the treatment of patients with documented herniated lumbar intervertebral discs whose symptoms and signs, particularly sciatica, had not responded to an adequate period of conservative therapy.

No rigorously established oral dosage protocols for isolated chymopapain as a dietary supplement exist in peer-reviewed or regulatory literature. Chymopapain appears in the enzyme mixture of papaya-based dietary supplement products, but doses in that context are not standardized to chymopapain activity specifically.

Safety: Notable, Source-Backed Considerations

Anaphylaxis

Anaphylaxis is the most prominent and historically significant safety concern with chymopapain injection. The overall reported incidence of anaphylaxis was approximately 0.5% to 1%, with variability across studies. The risk of allergic reaction could be mitigated with prior testing for allergic sensitivity to papain and/or preventative pretreatment with histamine-receptor antagonists. Other frequently reported adverse reactions included back pain and back spasm after injection. A recent meta-analysis including more than 10,000 patients treated with chymopapain (17 studies conducted from the late 1960s to 1980s) reported a rate of serious adverse events of 1.6% and a rate of anaphylaxis of 0.4%.

A survey covering 121 "serious" and "unexpected" adverse events after treatment with Chymodiactin among approximately 135,000 patients in the United States, reported to the FDA within 15 days of notification of the manufacturer between 1982 and the end of 1991, included: fatal anaphylaxis (seven cases), infections (24 cases), hemorrhage (32 cases), neurologic events (32 cases), and miscellaneous (15 cases) events, with a mortality rate of 0.019%. Anaphylactic reactions in a post-marketing survey could be attributed to chymopapain itself and infections to lack of asepsis during its administration.

Allergic reaction following chemonucleolysis with chymopapain is responsible for half of all known complications of this treatment. Although the incidence of allergic reactions is comparatively low, the danger involved should not be underestimated. If chemonucleolysis is performed under local anaesthesia, the risk of an anaphylactic reaction is reduced. If no pre-operative test methods are available, patient risk can be considerably lessened by suitable premedication and by keeping anti-allergics within easy reach during intradiscal therapy.

Neurological Adverse Events

Adverse reactions of chymopapain include anaphylaxis, discitis, subarachnoid hemorrhage, paraplegia, and acute transverse myelitis.

Paraplegia/paraparesis (e.g., as seen in cauda equina syndrome), other serious neurologic adverse events, and subarachnoid and intracerebral hemorrhage and seizures have been observed soon (within hours or days) after chymopapain injection at a rate of about 1 in 2,000. Causal relationships to the drug when properly injected have not been established. Needle trauma and/or injection of chymopapain and contrast media into the spinal fluid may be causes in some of these reported cases.

Chymopapain is potentially toxic in the subarachnoid space, especially when mixed with iodinated contrast, causing subarachnoid hemorrhage; thus, incorrect injection of chymopapain into spinal structures other than the disc could have serious adverse consequences.

Other less severe neurologic reactions included burning sacral and leg pain, hypalgesia, leg weakness, foot drop, cramping in both calves, pain in the opposite leg, paresthesia, tingling in legs, and numbness of legs/toes. The drug is extremely toxic when injected intrathecally in animals. Therefore, great caution must be exercised in assuring that chymopapain is not injected intrathecally into the dural canal.

Mortality

The overall mortality rate following chymopapain injection is approximately 1 in 5,000 patients (0.02%). For purposes of comparison, mortality associated with laminectomy has been reported to range from 0.02% to 0.1%.

Prior Exposure and Re-Treatment

Prior treatment with chymopapain is thought to sensitize the patient and increase the likelihood of an allergic reaction; however, repeat treatments have been shown to be safe and effective in some studies. A previous chymopapain injection is associated with increased risk of serious allergic reactions.

Contraindications

Contraindications for the use of chymopapain include known hypersensitivity to the enzyme, pregnancy, active infection, and severe spinal stenosis.

Drug Interactions

Given its enzymatic nature, chymopapain is unlikely to undergo significant metabolic interactions with hepatic enzymes such as CYP450. However, concurrent use of certain drugs may influence its safety and efficacy. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, commonly used in patients with back pain, should be used cautiously, as these drugs may mask early signs of infection or neurological complications post-chemonucleolysis, delaying diagnosis and treatment. Additionally, anticoagulants and antiplatelet agents such as warfarin and aspirin can increase the risk of bleeding complications during and after the procedure.

Context: Withdrawal and the Regulatory Record

Publicly available sources indicate that use of chymopapain had become controversial due to notable cases of fatal anaphylaxis and permanent neurological deficits. The FDA subsequently determined that Chymodiactin was not withdrawn from sale for reasons of safety or effectiveness. In 1982, the FDA approved chymopapain as a chemonucleolytic drug; however, chymopapain was discontinued in 1999 due to its low substrate specificity, disturbing nerve roots, and anaphylactic reactions. The commercial withdrawal was a business decision by the manufacturer; the FDA's formal determination clarified that no safety or efficacy-based regulatory action mandated the withdrawal.

References

• Wikipedia: Chymopapain
• ScienceDirect Topics: Chymopapain (Biochemistry)
• ScienceDirect Topics: Chymopapain (Medicine)
• Robinson GW. Isolation and characterization of papaya peptidase A from commercial chymopapain. Biochemistry. 1975.
• Buttle DJ et al. Chymopapain: chromatographic purification and immunological characterization. PubMed 1984.
• Clinical studies of chemonucleolysis patients with ten- to twenty-year follow-up evaluation. PubMed.
• Nordby EJ, Wright PH. Chemonucleolysis. PubMed. 1996.
• Hedtmann A et al. Chemonucleolysis using chymopapain and collagenase: 3-year results of a prospective randomized study. PubMed. 1992.
• Wittenberg RH et al. Five-year results from chemonucleolysis with chymopapain or collagenase: a prospective randomized study. PubMed. 2001.
• Bradford DS et al. Chymopapain, chemonucleolysis, and nucleus pulposus regeneration. PubMed. 1984.
• Gentry LR et al. Chymopapain chemonucleolysis: correlation of diagnostic radiographic factors and clinical outcome. PubMed. 1985.
• Agre K et al. Safety of chemonucleolysis: adverse effects reported in the United States, 1982–1991. PubMed. 1993.
• Javid MJ et al. Safety and efficacy of chymopapain (Chymodiactin) in herniated nucleus pulposus with sciatica. PubMed. 1983.
• Double-blind evaluation of intradiscal chymopapain for herniated lumbar discs: early results. PubMed.
• Degradation and biosynthesis of proteoglycans in the nucleus pulposus of canine intervertebral disc after chymopapain treatment. PubMed. 1988.
• Incidence and prevention of allergic reactions following chemonucleolysis with chymopapain. PubMed.
• Chemonucleolysis for Lumbar Disc Herniation: History and Current State of the Technology. PMC.
• Enzymatic chemonucleolysis for lumbar disc herniation — systematic review and meta-analysis. Scientific Reports. 2024. PMC.
• Chemonucleolysis in lumbar disc herniation: a meta-analysis. DARE Review. NCBI Bookshelf.
• Couto JMC et al. Chemonucleolysis in lumbar disc herniation: a meta-analysis. Clinics.
• Federal Register: Determination That Chymopapain 10,000 Units/Vial Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. 2003.
• FDA Briefing Document BLA 761393: Condoliase (includes discussion of chymopapain history).
• RxMed: Chymodiactin (Chymopapain) Monograph.
• Comparison of chemonucleolysis and discectomy in the management of lumbar disc herniation: a comprehensive systematic review and meta-analysis. PubMed. 2025.
• The efficacy and safety of condoliase for lumbar disc herniation: a systematic review and meta-analysis. PMC.
• Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know. Mayo Clinic Proceedings. 2014.
• Drugs.com Natural Product: Papaya.
• Therapeutic benefits of Carica papaya: A review on its pharmacological activities. Arabian Journal of Chemistry.
• Khatun et al. Extraction, purification and characterization of papain. Food Research. 2021.
• Carica Papaya — A Herbal Medicine. International Journal of Research Studies in Biosciences.
• Schol J et al. Enzymatic chemonucleolysis for lumbar disc herniation — a systematic review and meta-analysis. Scientific Reports. 2024.